Stockscreener 앱 받기
17.50
1.96%
-0.35
시간 외 거래:
17.50
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story - Sahm
Amneal receives FDA approval for additional iohexol strengths By Investing.com - Investing.com South Africa
Amneal receives FDA approval for additional iohexol strengths - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative
Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan
Amneal gains FDA approval for four iohexol products - grafa.com
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD - Investing.com
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating? - Sahm
Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - Ad-hoc-news.de
Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan
Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times
Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online
Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative? - Sahm
Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News
Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm
Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa
Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm
Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amneal Pharmaceuticals Inc - TradingKey
1.90%
1.24%
자본화:
|
볼륨(24시간):